Question for the board. Assuming regulatory sucess, which MS pts will BIIB/PDLI target with Daclizumab?
With 3 products for MS (Interferon, Tysabri, Daclizumab) is there a risk that BIIB will cannabilize sales of the other two drugs? Comments appreciated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.